REFERENCES
- Hellman, S., and D. Hellman. 1991. Of mice but not men: Problems of the randomized clinical trial. New England Journal of Medicine 324: 1585–1589.
- Light, D. W., and R. Warburton. 2011. Demythologizing the high cost of pharmaceutical research. BioSocieties 6: 34–50.
- Mirken, B. 1995. AIDS clinical trials: Why they have recruiting problems. AIDS Treatment News 217: 1–4.
- Nussbaum, B. 1990. Good intention: How big business and the medical establishment are corrupting the fight against AIDS, Alzheimer's, cancer and more. New York, NY: Penguin.
- Schuklenk, U. 1990. Access to experimental drugs in terminal illness: Ethical issues. Binghamton, NY: Pharmaceutical Products Press.
- Schuklenk, U., and C. Lowry. 2009. Terminal illness and access to Phase 1 experimental agents, surgeries and devices: Reviewing the ethical arguments. British Medical Bulletin 89: 7–22.
- Walker, M. J., W. A. Rogers, and V. Entwistle. 2014. Ethical justifications for access to unapproved medical interventions: An argument for (limited) patient obligations. American Journal of Bioethics 14(11): XX–XX.